Randy Carpenter, MD

Chief Medical Officer

Rett Syndrome Research Trust

Randy Carpenter, MD

March 23, 2023

DAYBUE (trofinetide): Key Facts for Parents

Randy Carpenter, MD

December 13, 2022

What We Learned from Taysha’s Clinical Trial Community Update

Randy Carpenter, MD

September 28, 2021

Outcomes of a Marathon FDA Meeting on the Safety of Gene Replacement

Randy Carpenter, MD

June 28, 2020

Enhancing the Potential Impact of Gene Therapy

Randy Carpenter, MD

February 25, 2020

Biomarkers - What are they and why do we need them?

Randy Carpenter, MD

January 24, 2019

On the Shoulders of Giants

Randy Carpenter, MD

October 31, 2018

UPDATE: AVXS-201 Gene Therapy for Rett Status

Randy Carpenter, MD

November 17, 2017

Preparing for Gene Therapy Trials

Randy Carpenter, MD

November 8, 2017

Breakthrough Discoveries for DNA & RNA Editing

Randy Carpenter, MD

May 15, 2017

Gene Therapy Consortium Reports on Progress

Randy Carpenter, MD

March 30, 2017

Orphan Drug Designation: What Does it Mean?

Randy Carpenter, MD

February 28, 2017

Key Questions to Ask When Considering Clinical Trials

Randy Carpenter, MD

January 27, 2017

Of Mice and Rett: Novel Therapeutics & Community Support

Randy Carpenter, MD

August 1, 2016

Results of Copaxone Open Label Trial

Randy Carpenter, MD

July 20, 2016

Ask Dr. Carpenter: Episode 1

Randy Carpenter, MD

June 20, 2016

First Impressions

Randy Carpenter, MD

February 29, 2016

A Word From Randy